Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure.
On June 4, 2018, Array BioPharma Inc. issued a press release announcing additional median overall survival results of encorafenib and binimetinib in patients with BRAF-mutant advanced melanoma that will be presented at the American Society of Clinical Oncology annual meeting. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
|
Item 7.01 |
Financial Statements and Exhibits. |
(d)Exhibits
|
ExhibitNo. |
Description |
|
99.1 |
Press release dated June 4, 2018.
|
ARRAY BIOPHARMA INC ExhibitEX-99.1 2 ascocolumbusdatareleasefin.htm EXHIBIT 99.1 Exhibit News Release Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma – Combination of encorafenib and binimetinib achieved 33.6 month median overall survival – – Data shows limited use of post-trial immunotherapy across treatment groups –– Phase 3 COLUMBUS results selected for “Best of ASCO” –– Encore investor webcast presentation today at 11:15 a.m. Central Time –Boulder,…To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
